Serum IL-17, IL-33, and different types of asthma treatments

Asthma is a heterogeneous disease, characterized by chronic airway inflammation in which many cells play a role in mediators’ production. The purpose of this study is to determine the serum IL-17 and IL-33 and defining the effect of the different types of therapy: ICS/LABA, ICS/LABA plus Tiotropium bromide and ICS/LABA plus Montelukast on these mediators in patients with uncontrolled moderate persistent asthma In study we included four groups. First group had 28 patients, who were treated with ICS/LABA therapy (100/6mcg, 2puffs twice daily). The second group had 28 patients on ICS/LABA plus Tiotropium bromide 5mcg daily. The third group had 28 patients on ICS/LABA plus Montelukast 10mg daily. The fourth, group consisted of 22 healthy participants. In each of them were measured serum IL-17, IL-33 levels by the ELISA method and lung function at the beginning and after 6 months of therapy. Results were statistically elaborated according to the Mann Whitney and Pearson test. The results showed that the serum IL-17(group 1; p=0.000004;p<0.05)(group 2; p=0.00004; p<0.05)(group 3; p=0.000007; p<0.05)and IL-33(group 1; p=0.000007; p<0.05)(group 2; p=0.011; p<005) (group 3; p=0.01; p<0.05) at the beginning were much higher and all treatments options significantly reduced their value. The difference in the average value of FEV1 before and after therapy was statistically significant only in the third group (t= 2.549, p=0.017;p<0.05). Identifying inflammation markers in asthma is crucial in defining the phenotype/endotype, making the proper diagnosis and therapy options, precise. The asthma treatment is necessary to reduce chronic inflammation and airway remodeling.